2008-07-24 23:54:13 -

www.kingpharm.com - King Pharmaceuticals, Inc. (NYSE:KG) reported today that the Company plans to announce its financial results for the second quarter ended June 30, 2008, prior to the market open on Thursday, August 7, 2008. The Company also plans to provide a live conference call which may include discussion of the Company's marketed products, pipeline, strategy for

growth, financial results and expectations, and other matters relating to its business beginning at 11:00 a.m., E.D.T., that same day. Interested persons may listen to the webcast by clicking on www.kingpharm.com/web_casts.asp. King will archive the webcast at this same link for not less than 14 days following the webcast for those unable to participate during the live webcast.

King, headquartered in Bristol, Tennessee, is a vertically integrated branded pharmaceutical company. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products in attractive markets and the strategic acquisition of branded products that can benefit from focused promotion and marketing and product life-cycle management.

This release contains forward-looking statements which reflect management's current views of future events and operations, including, but not limited to, statements pertaining to the anticipated date for release of the Company's financial results for the second quarter ended June 30, 2008. These forward-looking statements involve certain significant risks and uncertainties, and actual results may differ materially from the forward-looking statements. An important factor which may cause results to differ is whether King is able to release the Company's financial results for the second quarter ended June 30, 2008, as currently planned on August 7, 2008. Other important factors that may cause actual results to differ materially from the forward-looking statements are discussed in the "Risk Factors" section and other sections of King's Form 10-K for the year ended December 31, 2007 and Form 10-Q for the quarter ended March 31, 2008, which are on file with the U.S. Securities and Exchange Commission. King does not undertake to publicly update or revise any of its forward-looking statements even if experience or future changes show that the indicated results or events will not be realized.

King Pharmaceuticals, Inc.
James E. Green, 423-989-8125
Executive Vice President, Corporate Affairs
or
David E. Robinson, 423-989-7045
Senior Director, Corporate Affairs